logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10954232 B1

PDFFull Text
Date of Patent:
Mar. 23, 2021

Filed:

Jun. 30, 2017

Pyrazole derivative as alk5 inhibitor and uses thereof

Applicant:

Hanmi Pharmaceutical Co., Ltd., Hwaseong-si, KR;

Inventors:

Kyung Ik Lee, Hwaseong-si, KR;

Young Hee Jung, Hwaseong-si, KR;

Ji Young Song, Hwaseong-si, KR;

Seung Ah Jun, Hwaseong-si, KR;

Assignee:

HANMI PHARMACEUTICAL CO., LTD., Hwaseong-si, KR;

Attorney:

Sughrue Mion, PLLC

Primary Examiner:

Mark L Shibuya

Assistant Examiner:

Ebenezer O Sackey

Int. Cl.
CPC ...
C07D 471/04 (2006.01); C07D 417/14 (2006.01); C07D 401/14 (2006.01); C07D 405/14 (2006.01); C07D 413/14 (2006.01); C07D 403/04 (2006.01); A61K 31/4155 (2006.01); C07D 495/04 (2006.01); A61K 31/428 (2006.01); A61K 31/4725 (2006.01); A61P 19/04 (2006.01); A61P 17/02 (2006.01); A61P 11/00 (2006.01); A61P 19/10 (2006.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
C07D 471/04 (2013.01); A61K 31/4155 (2013.01); A61K 31/428 (2013.01); A61K 31/4725 (2013.01); C07D 401/14 (2013.01); C07D 403/04 (2013.01); C07D 405/14 (2013.01); C07D 413/14 (2013.01); C07D 417/14 (2013.01); C07D 495/04 (2013.01); A61P 11/00 (2018.01); A61P 17/02 (2018.01); A61P 19/04 (2018.01); A61P 19/10 (2018.01); A61P 35/00 (2018.01); Y02A 50/30 (2018.01);
Abstract

The present disclosure relates to a novel substituted pyrazole derivative having an effect of inhibiting serine/threonine kinase activity targeting receptor ALK5 of TGF-β, and a pharmaceutical composition including the compound of the present disclosure as an active ingredient may be useful in preventing and/or treating cancers, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, pulmonary diseases, cardiovascular diseases or metabolic diseases, or other diseases associated with a decrease in TGF family signaling activity.

Find Patent Forward Citations

Loading…